Envafolimab(KN035)* is an independently developed subcutaneous PD-L1 single-domain antibody Fc fusion protein. It was approved for marketing in China in November 2021, for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors.

Envafolimab efficiently blocks the binding of PD-1 and PD-L1, thereby activating an immune response against tumors. With a molecular weight half that of a conventional antibody, it exhibits enhanced tissue penetration and reaches tumor tissues via the lymphatic circulation system.

Envafolimab has been granted three Orphan Drug Designations (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced biliary tract cancer, soft tissue sarcoma and gastric cancer and gastroesophageal junction cancer; it has been granted Breakthrough Therapy Designation (BTD) by the NMPA for the treatment of unresectable or metastatic solid tumors with high tumor mutation burden (TMB-H).

Anbenitamab (KN026)* is an anti-HER2 bispecific antibody developed using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface.

In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the National Medical Products Administration (NMPA) for the treatment of HER2-positive gastric cancer (GC), and currently under review. Currently, several pivotal clinical trials of KN026 for first-line HER2-positive breast cancer (BC), neoadjuvant treatment and adjuvant treatment of HER2-positive BC are being conducted.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or low expressing GC; it has been granted Breakthrough Therapy Designation by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

Anbenitamab repodatecan (JSKN003) is developed by site-specific conjugation to the glycans on Fc of anbenitamab (KN026), resulting in a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4. JSKN003 binds to two HER2 epitopes on tumor cells and release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects.

JSKN003 demonstrates better serum stability, reduced hematological toxicity, and stronger tumor inhibition and bystander effect, resulting in significantly wider therapeutic window.

Patient enrollment has been completed for the Phase III clinical trial of JSKN003 in second-line HER2-positive breast cancer (BC), and a New Drug Application (NDA) is expected to be submitted in 2026. Additionally, several other registrational studies are ongoing, including trials in all-comer platinum-resistant ovarian cancer (PROC), HER2-low BC, and HER2-positive colorectal cancer (CRC).

JSKN016 is a TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4.

JSKN016 binds to TROP2 and/or HER3 on tumor cells and release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects.

JSKN016 has demonstrated promising antitumor activity and a favorable safety profile across multiple solid tumors. Multiple clinical studies of JSKN016 as monotherapy and in combination therapies for lung cancer, breast cancer, and other indications have been initiated. The Phase III clinical study evaluating JSKN016 for the treatment of triple-negative breast cancer (TNBC) is currently ongoing.

JSKN022 is a bispecific single-domain antibody targeting both PD-L1 and integrin αvβ6, developed through antibody-directed evolution. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4.

JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and topoisomerase I inhibitor payload to the antibody’s Fc region - maintaining a strong safety profile while unlocking potent anti-tumor activity.

JSKN021 is a first-in-class dual payload ADC consisting of an EGFR/HER3 bispecific antibody conjugated with novel topoisomerase I inhibitor (T01) and Monomethyl auristatin E (MMAE). Engineered with fine tuned binding avidity in both arms to address tumor heterogeneity while minimizing on-target, off-tumor toxicity, JSKN021 was designed for enhanced stability and improved homogeneity.

KN019 is a biosimilar of Belatacept (Nulojix^®).

KN019 has completed Phase II clinical study with positive results. In November 2023, KN019 received clinical trial approval from the National Medical Products Administration (NMPA) for its subcutaneous formulation.

KN046 is an independently developed PD-L1/CTLA-4 bispecific antibody, engineered to target the tumor microenvironment with high PD-L1 expression, and Treg (suppress tumor immunity) clearing function.

Multiple clinical trials of KN046 are ongoing in China, the U.S., and Australia.